Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

h low toxicity.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

About UCSF

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For more information, please see http://www.ucsf.edu.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not sup
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Boehringer Ingelheim will contribute to advancing ... American Thoracic Society International Conference (ATS 2013) in ... – 22. Data will highlight research ... of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® ... compounds for asthma, idiopathic pulmonary fibrosis (IPF) and ...
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... -- Chindex International, Inc. (NASDAQ: ... care services in China through the operations of United ... and affiliated ambulatory clinics, today announced that the Company ... and first half of 2011, which ended June 30, ...
... Apnex Medical, Inc., received investigational device exemption (IDE) approval ... begin a clinical study to evaluate the safety and ... treat obstructive sleep apnea (OSA). Data from this clinical ... application for the HGNS System to the FDA. ...
Cached Medicine Technology:Chindex International, Inc. to Report Financial Results for the Second Quarter and First Half of 2011 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 3
(Date:5/18/2013)... Morro Bay, CA (PRWEB) May 18, 2013 ... salon , has recently completed a stylish renovation that ... and advanced specialties. , From the ground up, this ... been improved with fresh flooring, soothing colors and comfortable ... have been installed, including an Apilus epilator machine. ...
(Date:5/18/2013)... Spectrum Surgical Instruments will attend the ... Austin, TX where thousands of GI nursing professionals ... , Spectrum Surgical/STERIS will feature its flexible ... capabilities and certified pre-owned equipment. Attendees will also ... instrument care of flexible endoscopes. , Visit ...
(Date:5/18/2013)... Miami, FL (PRWEB) May 18, 2013 ... accessories, is now offering its customers an attractive 25% ... Corkscrew. , Customers can now purchase this ... safe and secure online transactional process. The online store ... from the date of order placement. , A ...
(Date:5/18/2013)... UT (PRWEB) May 18, 2013 Medical device ... orders for its much anticipated mobility aid with its namesake, ... create a hands-free crutch alternative that injured individuals ... broken ankle, for example, can remain active and walk during ... is using its reservation system to ensure those who need ...
(Date:5/17/2013)... 18, 2013. Chronic trauma can inflict lasting damage to ... studies of people with post-traumatic stress disorder, or PTSD, ... in response to stressful tasks, such as recalling a ... threatening face. Now, researchers at NYU School of Medicine ... the brains of combat veterans with PTSD in the ...
Breaking Medicine News(10 mins):Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Now Save 25% on Franmara Dynamo Electric Wine Bottle Opener at Wine World Accessories 2Health News:FlexLeg Begins Offering New Mobility Aid 2Health News:For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests 2
... Jan. 28, 2009 Physical therapists at UT Southwestern ... people recovering from neurological injuries such as strokes and traumatic ... repeatedly practice movements needed to regain arm strength and movement. ... sites testing how the Armeo device, with its virtual environment ...
... with AsthmaWASHINGTON, Jan. 28 St. Louis, MO, is ranked ... to live with asthma in the U.S. (1) - according ... conducted the study. This ranking was determined based on an ... U.S. metro areas. (1) St. Louis was ranked No.1 this ...
... Relocated to Adjacent Proton Site in Warrenville CHICAGO, ... Illinois state approval on its plans to build ... in Warrenville. The Illinois Health Facilities Planning Board ... the project,s Certificate of Need application during today,s ...
... disease that,s harder to control, study says , , TUESDAY, ... of tuberculosis patients in the United States who say ... and difficult to treat than other TB patients, a ... patients aged 15 or older. Of those patients, 28,650 ...
... and Republican Party on Wrong TrackSACRAMENTO, Calif., Jan. 27 ... claimed that the Medicaid Family Planning State Option, a ... millions of women, would cost hundreds of millions of ... misleading attacks and partisan politics, was dropped from the ...
... ReportedCARLSBAD, Calif., Jan. 27 Jenny Craig, Inc. ... management, today announced a voluntary recall of its ... (UPC Code 655447009347) for U.S and P.R. distribution ... MAY2409BLO, MAY2509BLO, MAY2509ALO, MAY2609ALO, & MAY2609BLO, because the ...
Cached Medicine News:Health News:Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury 2Health News:Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury 3Health News:St. Louis Named Top Asthma Capital for 2009 2Health News:St. Louis Named Top Asthma Capital for 2009 3Health News:St. Louis Named Top Asthma Capital for 2009 4Health News:St. Louis Named Top Asthma Capital for 2009 5Health News:St. Louis Named Top Asthma Capital for 2009 6Health News:Central DuPage Hospital Wins State Approval to Build Cancer Center 2Health News:Central DuPage Hospital Wins State Approval to Build Cancer Center 3Health News:Substance Abuse Hinders TB Treatment 2Health News:Family Planning Provision Wrongfully Removed From Economic Stimulus Package 2Health News:Jenny Craig Announces Nationwide Voluntary Recall of Jenny's Cuisine(R) Anytime Peanut Butter Flavor Nutritional Bars Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... exchange in endourological procedures. The increased inner ... utilization of an extra heavy duty mandril ... flexible tip. The proximal end of this ... wire guide manufactured by Cook®. Supplied sterile ...
Medicine Products: